Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624090 · ClinicalTrials.gov registry record · Phase 2
Mithramycin for Lung, Esophagus, and Other Chest Cancers
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01624090: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01624090 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01624090, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Background: \- Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: \- To see if mithramycin is safe and effective against different chest cancers. Eligibility: \- Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum cancers. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment. * Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each 14-day round of treatment is called a cycle. * Treatment will be monitored with frequent blood tests and imaging studies. * Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment.
Interventions
- DRUG Mithramycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-09-06 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624090
The ClinicalTrials.gov registry entry for NCT01624090 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mithramycin is the first listed.
NCT01624090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01624090 about?
NCT01624090 is a clinical study titled "Mithramycin for Lung, Esophagus, and Other Chest Cancers". Background: \- Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. R...
What is the current status of trial NCT01624090?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-09-06. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT01624090?
The interventions under investigation include: Mithramycin (DRUG).
Who is sponsoring clinical trial NCT01624090?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.